Biochemistry and Structural Biology  Back to Main

Faculty Detail    
Campus Address ACC 512 Zip 0011
Phone  (205) 638-5855
Other websites

Faculty Appointment(s)
Appointment Type Department Division Rank
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Professor
Center  General Clinical Research Center  Ctr for Clinical & Translational Sci Professor
Primary  Pediatrics   Ped - Hematology/Oncology Professor

Graduate Biomedical Sciences Affiliations
Biochemistry and Structural Biology 

Biographical Sketch 
1975-1979 B.S., Biology Tulane University, New Orleans, LA 1979-1981 M.S., Immunology University of New Orleans, New Orleans, LA 1981-1985 M.D.Louisiana State University, New Orleans, LA 1985-1988 Pediatric Residency Tulane University School of Medicine New Orleans, LA 1988-1991 Clinical Fellow in Pediatric Hematology/Oncology University of Colorado Health Sciences Center Childrenís Hospital, Denver, CO 1989-1992 Postdoctoral Research Fellowship Immunology National Jewish Center for and Respiratory Medicine, Denver, CO 1993-1999 Assistant Professor University of Iowa College of Medicine Department of Pediatrics 1999-2009 Associate Professor University of Iowa College of Medicine Department of Pediatrics 2001-2009 Director, Pediatric Immune Disorders Clinic, University of Iowa College of Medicine 2001-2006 Director, Pediatric Bone Marrow Transplant Program, University of Iowa College of Medicine 2003-2009 Director, University of Iowa Hematopoietic Stem Cell Bank 2009-Present Professor of Pediatrics University of Alabama at Birmingham Division of Pediatric Hematology & Oncology Birmingham, AL 2009-Present Medical Director University of Alabama at Birmingham Lowder Bone Marrow Transplant Program

Society Memberships
Organization Name Position Held Org Link
American Society for Blood and Marrow Transplantation  Member   
American Society of Hematology  Member   
American Society of Pediatric Hematology/Oncology  Member   
International Bone Marrow Transplant `Registry  MemberNon-Malignant Marrow Disorders Working Committee   
Pediatric Bone Marrow Transplant Consortium  Member   

Research/Clinical Interest
Creation of patient-specific gene corrected hematopoietic stem cells in inherited bone marrow failure syndromes using inducible pluripotent stem cell technology
The major research interest of Dr. Goldmanís laboratory relates to understanding the molecular and immunologic mechanisms of bone marrow failure syndromes and congenital immune deficiencies, and translating this information to the promotion of novel stem therapies for these disorders. His work previously focused on Dyskeratosis congenita (DC) and he was involved in the discovery of the autosomal dominant form of this disease, AD DC. More recently, he has been involved in studies assessing the defect in hematopoietic stem cells in DC, and in collaboration with the Daley Lab at Dana Farber, applied iPS cell technology to correct the underlying deficiency in telomerase in reprogrammed DC cells. Studies are currently being performed that are assessing the role of telomerase in defects in oxidative stress and DNA repair. Dr. Goldman has also participated in pre-clinical gene therapy studies for a number of other bone marrow failure disorders and immune deficiencies, and has created an extensive tissue repository with patient samples from many different conditions, including Diamond Blackfan Anemia (DBA), Shwachman Diamond Syndrome, and Fanconiís anemia. More recently his research interests have shifted to DBA, and in concert with the Townes laboratory, is actively working on gene correction strategies for this condition using iPS cell technology and homologous recombineering. Through our collaboration with Dr. Lamb, the Director of the Stem Cell Processing laboratory and GMP facility at UAB, it is our collective hope that corrected patient iPS cells can be differentiated into hematopoietic stem cells for future transplantation into patients with DBA or other disorders of hematopoiesis.

Selected Publications 
Publication PUBMEDID
10.Goldman FD, Trigg, ME. Bone marrow transplantation for relapsed ALL. International Journal of Pediatric Hematology/Oncology, 5(2-4):215-230, 1998.   
13.Trigg ME, Goldman FD. Removing T-lymphocytes from bone marrow: present dangers and future benefits. Cancer Research Therapy and Control, January, 1998.   
36.Filipovich AH, Bleesing J, Goldman F. Emerging Targets for Hematopoietic Cell Transplantation (HCT): Genetic Disorders of Hematopoiesis and Immunity. Biol Blood Marrow Transplant, 2007, Jan;13S1:58-63.   
23.Kinet S, Bernard F, Mongellaz C, Perreau M, Goldman F, Taylor N. gp120-mediated induction of the MAPK cascade is dependent on the activation state of CD4+ lymphocytes. Blood, 100(7):2450-2456, 2002.  12239168  
16.Chen C-L, Levine A, Rao A, O’Neill K, Messinger Y, Myeers DE, Goldman F, Hurvitz, Casper JT, Uckun FM. Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-genistein in patients with B-lineage lymphoid malignancies. J Clin Pharmacol, 39(12):1248-55, 1999.  10586390 
15.Uckun FM, Messinger Y, Chen C, O’Neill K, Myers D, Levine A, Goldman F, Hurvitz C, Casper J, Uckum F. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clin Cancer Res, 5(12):3906-13, 1999.  10632319 
17.Goldman F, Rumelhart SL, Holida MD, Lee N, Trigg ME, Miller J, Giller R: Poor outcome in children with refractory/relapsed leukemia undergoing bone marrow transplantation with mismatched family member donors. Bone Marrow Transplant, 25, 943-948, 2000.  10800061 
18.Goldman F, Gilman A, Hollenback C, Kato R, Premack B, Rawlings D. Hydroxychloroquine inhibits calcium signals in T cells, a new mechanism to explain its immunomodulatory properties. Blood, 95(11):3460-66, 2000.
19.Gilman A, Chan K-W, Mogul M, Morris C, Goldman F, Boyer M, Cirenza E, Mazumder A, Cahill R, Frankel S, Schultz K: Hydroxychloroquine for the treatment for chronic graft-versus-host disease. Biol. Blood Marrow Transplant, 6 (3A), 327-34, 2000.  10905770 
20.Vulliamy T, Marrone A, Goldman F, Dearlove A, Bessler M, Mason Ph, Dokal I. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature, 413 (6854):432-5, 2001.
21.Fleitz J, Goldman F, Rumelhart S, Ambruso D, Sokol R, Pacini D, Quinones R, Holida M, Lee N, Tannous R, Giller R. Successful allogeneic hematopoietic stem cell transplantation (HSCT) for Schwachman-Diamond syndrome. Bone Marrow Transplant, 29:75-79, 2002.   11840149  
22.Goldman FD, Vibhakar R, Puck JM, Straus SE, Ballas ZK, Hollenback C, Loew T, Thompson A, Song K, Cook RT. Aberrant T-Cell Antigen Receptor-Mediated Responses in Autoimmune Lymphoproliferative Syndrome. Clin Immunol, 104(1): 31-39, 2002.  12139945 
24.Paulino A, Wen B-Chen, Tannous R, Mayr N, Loew T, Goldman F, Ryken T, Buatti J. Protracted Radiotherapy Treatment Duration is Detrimental in Medulloblastoma. Am J Clin Oncol. 2003; Feb; 26(1):55-59.  12576926  
25.Lynch BA, Vasef MA, Comito M, Gilman AL, Lee N, Ritchie J, Rumelhart S, Holida M, Goldman, F. Effect of in vivo lymphocyte-depleting strategies on development of lymphoproliferative disorders in children post allogeneic bone marrow transplantation. Bone Marrow Transplant, 2003; Sep; 32(5):527-33.   12942101 
26.Stepanovic V, Wessels D, Goldman FD, Geiger J, Soll D. The Chemotaxis Defect of Shwachman-Diamond Syndrome Leukocytes. Cell Motil Cytoskeleton, 2004; Mar; 57(3):158-174.   14743349 
27.Knudson M, Kuklarni S, Ballas Z, Bessler M, Goldman F. Association of Immune Abnormalities with Telomere Shortening in Autosomal Dominant Dyskeratosis Congenita. Blood, 105(2):684-690, 2005.  15238429 
28.Corey S, Weitman S, Rytting M, Elopre M, Rumelhart S, Goldman FD. Complete Remission Following Clofarabine Treatment in Refractory Juvenile Myelomonocytic Leukemia. J Pediatr Hematol Oncol, 2005; Mar 27(3):166-8.   15750451 
30.Grossman WJ, Radhi M, Schauer D, Gerday E, Grose C, Goldman FD. Development of hemophagocytic lymphohistiocytosis in triplets infected with HHV-8. Blood. 2005 Aug 15; 106(4):1203-6  15840696 
29.Alsultan A, Williams M, Lubner S, Goldman F. Chronic Granulomatous Disease Presenting with Disseminated Intracranial Aspergillosis, Case Report and Review of the Literature. Pediatr Blood Cancer. 2005 Jun 1; [Epub ahead of print] .PMID: 15931655  15931655  
32.Vibhakar R, Radhi M, Rumelhart S, Tatman D, Goldman F. Successful Unrelated Umbilical Cord Blood Transplantation in Children with Shwachman-Diamond Syndrome. Bone Marrow Transplant. 2005, 36:855-861.  16113664 
31.Rackley C, Schultz KR, Goldman FD, Chan KW, Serrano A, Hulse JE, Gilman AL. Cardiac Manifestations of Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2005 Oct; 11(10):773-780.  16182178 
33.Goldman F, Bouarich R, Kulkarni S, Freeman S, Du H, Harrington L, Mason PJ, Londono-Vallejo A, Bessler, M. The effect of TERC haploinsufficiency on the inheritance of telomere length. Proc Natl Acad Sci. 2005,
Nov 22; 102(47):17119-24.
34.Pashankar F, Singhal V, Gatti R, Akabogu I, Goldman F. Intact T Cell Responses in Ataxia Telangiectasia, Clin Immunol, 2006, Aug; 120(2):156-62. [Epub 2006 June 8].
38.Fine RL, Shah SS, Yu IR, Moulton TA, Fogelman DR, Richardson M, Burris HA, Samuels BL, Assanasen C, Gorroochurn P, Goldman FD, Dubovsky D, Walterhouse D, Halligan G. Androgen and c-Kit receptors in desmoplastic small round cell tumors (DSRCT) resistant to chemotherapy: novel targets for therapy. Cancer Chemother Pharmacol. 2007, Mar; 59(4):429-437. {Epub 2006 Aug 3}.   16896931  
35.Shelton BK, Griffin JM, Goldman FD. IGIV Therapy: Optimizing Care of Patients in the Oncology Setting. Oncol Nurs Forum. 2006, Sep 1; 33(5):911-21  16955119 
37.Radhi M, Rumelhart S, Tatman D, Goldman F. Severe autoimmune hemolytic anemia after unrelated umbilical cord blood transplant for familial hemophagocytic lymphohistiocytosis: significant improvement after treatment with rituximab. J Pediatr Hematol Oncol. 2007, Feb.29 (2):125-7.  17279011  
40.Westin ER, Chavez E, Lee KM, Gourronc FA, Riley S, Lansdorp PM, Goldman FD, Klingelhutz AJ. Telomere Restoration and Extension of Proliferative Lifespan in Dyskeratosis Congenita Cells. Aging Cell, 2007 Jun;6(3):383-94 Epub 2007 Mar 23  17381549  
39.She K,. Gilman A, Aslanian A, Shimizu H, Krailo M, Chen W, Reid G, Wall D, Goldman F, Schultz K. Altered TLR9 Responses in Circulating B cells at the Onset of Chronic GVHD, Biol Blood Marrow Transplant, 2007 Apr;13(4):386-97. Epub 2007 Feb 15.  17382246 
41.Widness JA, Al-Huniti NH, Schmidt RL, Hohl RJ, Goldman FD, Veng-Pedersen P. Change in Erythropoietin Pharmacokinetics Following Hematopoietic Transplantation. Clin Pharmacol Ther, 2007 Jun;81(6):873-9. Epub 2007 Apr 11.  17429351 
42 Fujii H, Cuvelier G, She K, Aslanian S, Shimizu H, Kariminia A, Krailo M, Chen Z, McMaster R, Goldman F, Grupp SA, Wall DA, Gilman AL, Schultz KR. Biomarkers in Newly Diagnosed Pediatric Extensive Chronic Graft-versus-Host Disease. Blood, 2008 Mar 15; 111(6):3276-85. Epub 2007 Oct 9.
43 Goldman FD, Aubert G, Klingerlhutz AJ, Hills M, Cooper SR, Hamilton WS, Schluter AJ,Eaves CJ, Lansdorp PM. Characterization of Primitive Hematopoietic Cells from Patients with Dyskeratosis Congenita. Blood, 2008May 1; 111(9):4523-31. Epub 2008 Feb 29.
44.Du HY, Pumbo E, Ping A, Bagby GC, Maziarz RT, Reiss UM, Chirnomas D, Shimamura A, Vlachos A, Lipton JM, Goyal RK, Goldman F, et al. TERC and TERT Gene Mutations in Patients With Bone Marrow Failure and the Significance of Telomere Length Measurements. Blood, Epub 2008 Oct 17.   18931339 
45.Gourronc F, Robertson M, Herrig A, Goldman F , Klingelhutz A. Amelioration of Proliferative and Functional Defects in Dyskeratosis Congenita Keratinocytes by Activation of TERT or Exogenous Expression of TERC. Experimental Dermatol, June 23 2009 [Epub ahead of print]  19558498 
47.Heath J, Goldman F. Idiopathic Thrombocytopenic Purpura in a Boy with Ataxia Telangiectasia on Immunoglobulin Replacement Therapy. J Pediatr Hematol Oncol. 2010 Jan;32(1):e25-7  20051773  
48.Nalbant D, Saleh M, Goldman D, Widness J, Veng-Pedersen P. Evidence of receptor-mediated elimination of erythropoietin by analysis of Epo receptor mRNA expression in bone marrow and erythropoietin clearance during anemia J Pharmacol Exp Ther. 2010 Jan 26. [Epub ahead of print]  20103588 
46.Agarwal S, Loh YH, Park IH, Huang J, McLoughlin EM, Miller JD, Reis RMD, Okuka M, Huo H, Loewer S Goldman FD, Keefe D, Klingelhutz AJ, Liu L, Daley GQ. Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature, Epub 2010 Feb 17  20164838 
49.Cuvelier G, Kariminia A, Fujii H, Aslanian S, Wall D, Goldman F, Grupp S, Krailo M, Shapiro L, Gilman A, Schultz K Anti-CD13 antibodies present after allogeneic blood and marrow transplantation are not induced by soluble CD13 and are not biomarkers for extensive chronic graft-versus-host disease. Bone Marrow Transplant. 2010 Mar 1. [Epub ahead of print]  20190833 
50.McDonald D*,Goldman F*, Geha R. T Cell Antigen Receptor Signaling Defects in Patients with IRAK-4 deficiency. J Allergy Clin Immunol. 2010 Aug; 126(2):332-7, 337.e1-2  20621347 
51.Chu R, Brazauskas R, Kan F, Bashey A, Bredeson C, Camitta B, Chiang KY, Frangoul H, Gale RP, Gee A, George B, Goldman FD, Gross TG, Gupta V, Hale GA, Isola L, Ispizua AU, Lazarus H, March J, Russell J, Sabloff M, Waller EK, Eapen M. Comparison of Outcomes after Transplantation of G-CSF Stimulated Bone Marrow Grafts versus Bone Marrow or Peripheral Blood Grafts from HLA-Matched Sibling Donors for Patients with Severe Aplastic Anemia. Biol Blood Marrow Transplant. 2010 Oct 26 [Epub ahead of print]  21034842 
52.Westin ER, Aykin-Burns N, Buckingham EM, Spitz DR, Goldman FD, Klingelhutz AJ. The p53/p21WAF/CIPPathway Mediates Oxidative Stress and Senescence in Dyskeratosis Congenita Cells wit Telomerase Insufficiency. Antioxid Redox Signal. 2010 Nov 18. [Epub ahead of print]  21087144  
54.Tawfik D, Walsch A, Cowan K, Hamilton W, Goldman F. Exogenous Immunoglobulin Downregulates T Cell
Receptor Signaling and Cytokine Production. Pediatr Allergy Immunol. 2011 Jan 25. [Epub ahead of print]
58.Ataga KI, Reid M, Ballas SK, Yasin Z, Bigelow C, James LS, Smith WR, Galacteros F, Kutlar A, Hull JH, Stocker JW; ICA-17043-10 Study Investigators. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).Br J Hem. 2011 Apr;153(1):92-104  21323872  
57.Goldman FD, Gurel Z, Al-Zubeidi D, Freed A, Icardi M, Song C, Dovat S. Congenital Pancytopenia and Absence of B Lymphocytes in a Neonate with a Mutation in the Ikaros Gene. Pediatr Blood Cancer. 2011 May [Epub ahead of print]  21548011 
Rozmus J, Schultz KR, Wynne K, Kariminia A, Satyanarayana P, Krailo M, Wall D, Gilman AL, Goldman FD. Early and Late Extensive Chronic Graft-Versus-Host Disease (cGVHD) In Children is Characterized by
Different Th1/Th2 Cytokine Profiles: Findings of the Children’s Oncology Group Study (COG), ASCT0031,Biol Blood Marrow Transplant, May 25 2011 [Epub ahead of print].
1.Goldman F, Rotbardt H, Guitterez K, Ambruso D. Parvovirus associated aplastic crisis in a patient with red cell glucose 6-phosphate dehydrogenase deficiency. Pediatric Infectious Disease Journal, 9:593-594, 1990.  2172909 
55.Gilman AL, Schultz KR, Goldman FD, Sale GE, Krailo MD, Chen Z, Langholz B, Jacobsoh DA, Chan, KW,
Ryan RE, Kellick M, Neudorf SM, Godder K, Sandler ES, Sahdev I, Grupp SA, Sanders JE, Wall DA. Randomized Trial of Hydroxychloroquine for Newly-diagnosed Chronic Graft-versus-Host Disease in Children: A Children’s Oncology Group Study, in press, Biol Blood Marrow Transplant, 2011.
53.Gilman AL, Bunin N, Levine J, Goldman FD, Joyce M, Bendel A, Anderson P, Pietryga D, Anderson R,
Rozans M, Wall D, McDonald T, Sambrano J, Simon S, Hetherington M, Kadota RP. Phase I Study of Dual
Cycle High-dose Chemotherapy with Autologous Peripheral Blood Stem Cell Rescue for Patients with Recurrent Brain Tumors: A Pediatric Blood and Marrow Transplant Consortium Study. Pediatr Blood Cancer. 2010 Dec 1. [Epub ahead of print]
59.Goldman FD, Whelan K. Editorial on “Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable risk Hodgkin lymphoma. JAMA 2012 Jun 27;307(24):2639-41.  22735435 
5.Goldman F, Jensen WA, Johnson GL, Heasley L, Cambier JC. gp120 ligation of CD4 induces p56lck activation and TCR desensitization independent of TCR tyrosine phosphorylation. Journal of Immunology, 153:2905-2917, 1994.  7522245  
4.Donovan J, Goldman F, Koretzky G. Restoration of CD2-mediated signaling by chimeric membrane protein including the cytoplasmic sequence of CD45. Human Immunology, 40:123-30, 1994  7928441  

gene therapy, telomerase, hematopoiesis, inducible pluripotent stem cells, oxidative stress, DNA damage response pathways